Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (151)	4/8/1998 1:27:00 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 550

To: Mr. Kevin Kwok Director, IR Department SUGEN Inc. Sir, Thanks very much for today long and helpful conversation in regards my e-mail and questions which are addressed in it. I was forced, without my will, to post my last message on this board because I was very disappointed with Your delayed attention. I understand that many answers on my questions content confidential Company information and will not be disclosed, still other ones were open for discussion. Hope You understand my frustration and reasons for tone in post.. Except my apologize if I offended You. Anyway, this unfortunate is history and we can continue with good relationship as we promise to each others. Best regards, Dr. Miljenko Zuanic Note: I can't and will not post details of my discussion with Mr. Kevin Kwok. It was in relation to SUGEN cancer projects and drug pipeline. I can say that I am pleased with their projects and future company potential. Regardless that some issues in relation to SU101 are not completely solved and some concern remain, together with SUGN SU5416 and several other cancer drugs SUGN appears to be one of the fast growing and very promising early stage biotechnology company. I have wasted interest in SUGN, so anyone is advised to do his own homework.